Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?

Chi Young Ok, Qing Ye, Ling Li, Ganiraju C. Manyam, Lijuan Deng, Rashmi R. Goswami, Xiaoxiao Wang, Santiago Montes-Moreno, Carlo Visco, Alexandar Tzankov, Karen Dybkaer, Li Zhang, Jeremy Abramson, Aliyah R. Sohani, April Chiu, Attilio Orazi, Youli Zu, Govind Bhagat, Kristy L. Richards, Eric D. Hsi & 14 others William W.L. Choi, J. Han van Krieken, Jooryung Huh, Maurilio Ponzoni, Andrés J.M. Ferreri, Shanxiang Zhang, Ben M. Parsons, Mina Xu, Michael B. Møller, Jane N. Winter, Miguel A. Piris, Zijun Y. Xu-Monette, L. Jeffrey Medeiros, Ken H. Young

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in =50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.

Original languageEnglish (US)
Pages (from-to)13933-13945
Number of pages13
JournalOncotarget
Volume6
Issue number16
DOIs
StatePublished - Jan 1 2015

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Human Herpesvirus 4
Gene Expression Profiling
MicroRNAs
Lymphoma
B-Lymphocytes
History
Cell Proliferation

Keywords

  • DLBCL
  • EBV
  • Elderly
  • Gene expression profiling

ASJC Scopus subject areas

  • Oncology

Cite this

Ok, C. Y., Ye, Q., Li, L., Manyam, G. C., Deng, L., Goswami, R. R., ... Young, K. H. (2015). Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary? Oncotarget, 6(16), 13933-13945. https://doi.org/10.18632/oncotarget.4324

Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary? / Ok, Chi Young; Ye, Qing; Li, Ling; Manyam, Ganiraju C.; Deng, Lijuan; Goswami, Rashmi R.; Wang, Xiaoxiao; Montes-Moreno, Santiago; Visco, Carlo; Tzankov, Alexandar; Dybkaer, Karen; Zhang, Li; Abramson, Jeremy; Sohani, Aliyah R.; Chiu, April; Orazi, Attilio; Zu, Youli; Bhagat, Govind; Richards, Kristy L.; Hsi, Eric D.; Choi, William W.L.; van Krieken, J. Han; Huh, Jooryung; Ponzoni, Maurilio; Ferreri, Andrés J.M.; Zhang, Shanxiang; Parsons, Ben M.; Xu, Mina; Møller, Michael B.; Winter, Jane N.; Piris, Miguel A.; Xu-Monette, Zijun Y.; Medeiros, L. Jeffrey; Young, Ken H.

In: Oncotarget, Vol. 6, No. 16, 01.01.2015, p. 13933-13945.

Research output: Contribution to journalArticle

Ok, CY, Ye, Q, Li, L, Manyam, GC, Deng, L, Goswami, RR, Wang, X, Montes-Moreno, S, Visco, C, Tzankov, A, Dybkaer, K, Zhang, L, Abramson, J, Sohani, AR, Chiu, A, Orazi, A, Zu, Y, Bhagat, G, Richards, KL, Hsi, ED, Choi, WWL, van Krieken, JH, Huh, J, Ponzoni, M, Ferreri, AJM, Zhang, S, Parsons, BM, Xu, M, Møller, MB, Winter, JN, Piris, MA, Xu-Monette, ZY, Medeiros, LJ & Young, KH 2015, 'Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?', Oncotarget, vol. 6, no. 16, pp. 13933-13945. https://doi.org/10.18632/oncotarget.4324
Ok, Chi Young ; Ye, Qing ; Li, Ling ; Manyam, Ganiraju C. ; Deng, Lijuan ; Goswami, Rashmi R. ; Wang, Xiaoxiao ; Montes-Moreno, Santiago ; Visco, Carlo ; Tzankov, Alexandar ; Dybkaer, Karen ; Zhang, Li ; Abramson, Jeremy ; Sohani, Aliyah R. ; Chiu, April ; Orazi, Attilio ; Zu, Youli ; Bhagat, Govind ; Richards, Kristy L. ; Hsi, Eric D. ; Choi, William W.L. ; van Krieken, J. Han ; Huh, Jooryung ; Ponzoni, Maurilio ; Ferreri, Andrés J.M. ; Zhang, Shanxiang ; Parsons, Ben M. ; Xu, Mina ; Møller, Michael B. ; Winter, Jane N. ; Piris, Miguel A. ; Xu-Monette, Zijun Y. ; Medeiros, L. Jeffrey ; Young, Ken H. / Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?. In: Oncotarget. 2015 ; Vol. 6, No. 16. pp. 13933-13945.
@article{f7234c5e47194d5184a7f03f2bf93883,
title = "Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?",
abstract = "Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in =50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.",
keywords = "DLBCL, EBV, Elderly, Gene expression profiling",
author = "Ok, {Chi Young} and Qing Ye and Ling Li and Manyam, {Ganiraju C.} and Lijuan Deng and Goswami, {Rashmi R.} and Xiaoxiao Wang and Santiago Montes-Moreno and Carlo Visco and Alexandar Tzankov and Karen Dybkaer and Li Zhang and Jeremy Abramson and Sohani, {Aliyah R.} and April Chiu and Attilio Orazi and Youli Zu and Govind Bhagat and Richards, {Kristy L.} and Hsi, {Eric D.} and Choi, {William W.L.} and {van Krieken}, {J. Han} and Jooryung Huh and Maurilio Ponzoni and Ferreri, {Andr{\'e}s J.M.} and Shanxiang Zhang and Parsons, {Ben M.} and Mina Xu and M{\o}ller, {Michael B.} and Winter, {Jane N.} and Piris, {Miguel A.} and Xu-Monette, {Zijun Y.} and Medeiros, {L. Jeffrey} and Young, {Ken H.}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.4324",
language = "English (US)",
volume = "6",
pages = "13933--13945",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "16",

}

TY - JOUR

T1 - Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary?

AU - Ok, Chi Young

AU - Ye, Qing

AU - Li, Ling

AU - Manyam, Ganiraju C.

AU - Deng, Lijuan

AU - Goswami, Rashmi R.

AU - Wang, Xiaoxiao

AU - Montes-Moreno, Santiago

AU - Visco, Carlo

AU - Tzankov, Alexandar

AU - Dybkaer, Karen

AU - Zhang, Li

AU - Abramson, Jeremy

AU - Sohani, Aliyah R.

AU - Chiu, April

AU - Orazi, Attilio

AU - Zu, Youli

AU - Bhagat, Govind

AU - Richards, Kristy L.

AU - Hsi, Eric D.

AU - Choi, William W.L.

AU - van Krieken, J. Han

AU - Huh, Jooryung

AU - Ponzoni, Maurilio

AU - Ferreri, Andrés J.M.

AU - Zhang, Shanxiang

AU - Parsons, Ben M.

AU - Xu, Mina

AU - Møller, Michael B.

AU - Winter, Jane N.

AU - Piris, Miguel A.

AU - Xu-Monette, Zijun Y.

AU - Medeiros, L. Jeffrey

AU - Young, Ken H.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in =50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.

AB - Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly (EBV+ DLBCL-e) is a molecularly distinct variant of DLBCL, characterized by a monoclonal B-cell proliferation that occurs in patients >50 years of age without a history or clinicopathologic evidence of immunodeficiency. However, patients with EBV+ DLBCL younger than 50-years-old also exist in Western countries. We evaluated the clinicopathologic, immunophenotypic and genetic features in Cacausian patients with EBV+ DLBCL who are ≤50 years of age and compared this patient group to patients who are >50 years. In patients who are ≤50 years, less frequent expression of BCL6 and a trend of more frequent expression of CD30 and pSTAT3 were found in patients with EBV+ DLBCL. In patients who are >50 years, common expression of CD30, p50, pSTAT3 and less frequent expression of BCL6 were observed. Older patients also more commonly had a poor performance status (ECOG≥2). Comparing EBV+ DLBCL patients in =50 years versus >50 years, both groups had similar clinicopathologic, immunophenotypic and genetic features. Gene expression profiling, microRNA profiling and treatment outcome of the younger patients with EBV+ DLBCL was not distinctive from tumors in older patients. Based on our data, we suggest that the arbitrary age cutoff for EBV+ DLBCL is unnecessary and should be eliminated in the WHO lymphoma classification scheme.

KW - DLBCL

KW - EBV

KW - Elderly

KW - Gene expression profiling

UR - http://www.scopus.com/inward/record.url?scp=84979937414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979937414&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4324

DO - 10.18632/oncotarget.4324

M3 - Article

VL - 6

SP - 13933

EP - 13945

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 16

ER -